engineering and study of protein function by directed evolution has been limited by the technical requirement to use global mutagenesis or introduce dnA libraries. here, we develop crisPr-X, a strategy to repurpose the somatic hypermutation machinery for protein engineering in situ. using catalytically inactive dcas9 to recruit variants of cytidine deaminase (Aid) with ms2-modified sgrnAs, we can specifically mutagenize endogenous targets with limited off-target damage. this generates diverse libraries of localized point mutations and can target multiple genomic locations simultaneously. We mutagenize GFP and select for spectrum-shifted variants, including eGFP. Additionally, we mutate the target of the cancer therapeutic bortezomib, PsmB5, and identify known and novel mutations that confer bortezomib resistance. Finally, using a hyperactive Aid variant, we mutagenize loci both upstream and downstream of transcriptional start sites. these experiments illustrate a powerful approach to create complex libraries of genetic variants in native context, which is broadly applicable to investigate and improve protein function.
Directed evolution employs successive rounds of mutation and selection to engineer biomolecules such as antibodies and enzymes with enhanced or novel functions [1] [2] [3] . A major limitation to these experiments is the generation and maintenance of a diverse mutant population. Global mutagenesis with radiation or chemically induced DNA damage requires maintenance of a large number of cells, since most mutations are located outside the target of interest. Alternatively, plasmid libraries can be introduced into cells; however, these proteins are often expressed at inappropriate levels and without normal regulation. Importantly, these libraries are of limited diversity and length, greatly restricting the potential for evolution experiments. In addition, mammalian proteins engineered in bacteria, bacteriophage, and yeast [4] [5] [6] often change behavior in their native host environment. Hence, generating a diverse library of mutants in native context would have enormous advantages.
Nature has a built-in mechanism for generating diversity at a specific genetic locus, which is used with exquisite precision during the process of antibody maturation. After V-D-J recombination, directed evolution using dcas9-targeted somatic hypermutation in mammalian cells B cells create point mutations in their immunoglobulin (Ig) regions through the process of somatic hypermutation (SHM) to perform antibody affinity maturation 7, 8 . SHM is mediated by an enzyme called activation-induced cytidine deaminase (AID), which deaminates a cytosine (C) to a uracil (U), initiating a DNA repair response that causes errors in the Ig locus at a rate of 1/1,000 bp −1 (ref. 9 ). The process generates point mutations rather than insertions and deletions, and it favors transitions over transversions 8 . After deamination, mutations can be generated in three ways: (i) the uracil-guanine (U-G) mismatch can be misread, resulting in a (C>T) or (G>A) transition; (ii) the U can be removed by base-excision repair and replaced by any base; (iii) or an error-prone translesion polymerase can be recruited through the mismatch-repair pathway, generating transitions and transversions near the lesion 7 .
Although sequence elements flanking the Ig locus have been linked to SHM targeting 10 , the mechanisms by which SHM is regulated and targeted are not completely understood. It has been proposed that AID migrates with the RNA polymerase II complex during transcription of the Ig locus and mutates specific hotspot sequence motifs 11, 12 . Cell lines that misregulate or overexpress AID have the mutagenic capacity to evolve both fluorescent proteins 13, 14 and antibodies 15 , but this creates potentially deleterious mutations throughout the genome 16, 17 .
Catalytically dead Cas9 (dCas9) has been used to target functional proteins to specific genomic loci for repression and activation of transcription [18] [19] [20] [21] , fluorescent tracking 22, 23 , enzymatic modification [24] [25] [26] [27] , and recently for conversion of C>T as a means of therapeutic editing 24, 27 . Here, we use dCas9 to target hyperactive AID to induce localized, diverse point mutations (a strategy we have termed CRISPR-X). This process differs markedly from mutagenesis using active Cas9 (ref. 28) , which predominantly generates insertions and deletions [29] [30] [31] , or the introduction of mutations via oligonucleotide donor libraries by homologous recombination following Cas9 cleavage 32, 33 . We then illustrate the potential of this novel targeted mutagenesis strategy for the engineering and evolution of new protein function in normal cellular context. results targeted mutagenesis through dcas9 recruitment of Aid In order to recruit AID, we used dCas9 (ref. 31 ) combined with a single guide RNA (sgRNA) bearing two MS2 hairpin-binding sites (Fig. 1a) , a combination that was previously used to recruit MS2-fused effector proteins to activate transcription 21 . Using sgRNAs targeting GFP and loss of fluorescence as a proxy for mutagenesis, we investigated the ability of various dCas9-directed MS2-AID fusions to create targeted mutations in K562 cells expressing GFP and mCherry (see Supplementary Note 1 and Supplementary  Fig. 1 ). We found that deletion of the nuclear export signal of AID (AID∆) enhanced GFP mutagenesis using electroporated sgRNAs but did not cause off-target mutation of mCherry. We then tested a lentivirally integrated version of the CRISPR-X system to mutagenize GFP; sequencing of GFP revealed mutations enriched near the targeted region but not at an mCherry locus (see Supplementary Note 1, Fig. 1b, and Supplementary Fig. 2 ). In contrast, use of a control sgRNA or catalytically inactive MS2-AID∆Dead did not induce mutations at either location.
defining the region of mutagenesis for crisPr-X To determine the region of mutagenesis, we selected an additional 11 sgRNAs (sgGFP.2-12) tiling the GFP locus on both strands ( Fig. 1c and Supplementary Fig. 3a) . Since AID mutagenesis has been shown to require transcription 11 , we hypothesized the strand of the guide relative to the direction of transcription may change the targeting of mutations. We sequenced the GFP locus in each sample and mapped mutations relative to the end of the protospacer-adjacent motif (PAM) sequence of each sgRNA ( Fig. 1c and Supplementary Fig. 3b ). While different sgRNAs exhibited a range of mutation efficiencies (Supplementary Fig. 3c ), we observed a mutational hotspot region from +12 to +32 bp downstream of the PAM relative to the direction of transcription that was independent of strand targeting (Fig. 1c) . The mutational hotspot was defined to include any base with at least ten-fold increased mutation over all three independent infections for a given sgRNA. A median mutation frequency of 0.0104 was measured for the 12 sgGFP guides within each hotspot, a frequency markedly higher than that observed with nontargeting sgRNAs or catalytically inactive AID (Supplementary Fig. 3d ). This translates to a mutation rate of ~1/2,000 bp −1 , which is similar to that observed for somatic hypermutation 8 . Given the ability of this system to generate targeted point mutations, we sought to apply it in directed evolution experiments. evolution of wild-type GFP to eGFP using crisPr-X As an initial proof of principle, we tested whether we could alter an integrated copy of wild-type GFP (wtGFP) from Aequorea victoria (excitation, 395 nm; emission, 509 nm) to EGFP (490/509 nm) 34 . EGFP has two mutated residues from wtGFP: S65T, which shifts the excitation-emission (ex-em) spectrum, and F64L, which improves the folding kinetics of GFP [34] [35] [36] . We designed four guides (sgwtGFP.1-4) that targeted this region and introduced them via electroporation along with MS2-AID∆ into K562 cells expressing dCas9 and wtGFP. As a negative control, we also electroporated four safe-targeting sgRNAs targeting genomic regions annotated as nonfunctional. Cells were grown for 10 d to introduce mutations, and then they were FACS sorted to collect cells expressing spectrum-shifted GFP (Fig. 2a) . In replicate experiments, we observed a population with decreased signal in the Pacific blue channel and increased GFP signal (0.076% replicate 1, 0.025% replicate 2) ( Fig. 2b and Supplementary Fig. 4a) , which was not observed in the safe-targeted samples ( Fig. 2b and Supplementary Fig. 4a ). After another round of sorting, only the GFP-targeted samples had a spectrum-shifted population, which increased markedly in both replicates.
The GFP locus was sequenced to identify mutations enriched by sorting (Supplementary Fig. 4a ), revealing increased mutations at positions 331 (G>C) and 377 (G>C). The former variant introduces the known EGFP S65T mutation (Supplementary Fig. 4a ). The latter mutation generated a Q80H substitution, which we ezomib selection, and the presence of the expected mutation was verified in the majority of nonframeshifted sequences (Supplementary Fig. 6 ). Together, these experiments show that CRISPR-X can be used to selectively mutagenize an endogenously expressed protein, identifying known and novel mutants that confer drug resistance.
enhanced mutagenesis using a hyperactive Aid mutant (Aid*D) We observed variable mutation efficiency with AID∆; therefore, we investigated whether this could be improved further with AID variants previously shown to have increased SHM activity 40 . We selected one of the strongest mutants (AID*) and removed its NES as we had with wild-type AID (Supplementary Fig. 1a) . The resulting AID*∆ was integrated along with one of three sgRNAs (sgGFP.3, sgGFP.10, and sgSafe.2), and mutations in GFP and mCherry loci were quantified ( Fig. 4a and Supplementary Fig. 7a ). Despite lower expression of AID*∆ (Supplementary Fig. 1c) , we observed ~10-fold increase in mutation at the most enriched base position for GFP-targeting sgRNAs when compared with suspected was a passenger mutation, since the majority of sequences containing the mutation also contained S65T. To determine the contribution of each mutation to altered fluorescence, we separately introduced each into GFP and confirmed that the S65T mutation alters the fluorescence spectrum of GFP; whereas Q80H, either alone or together with S65T, does not ( Fig. 2c) .
We did not observe the F64L mutation, which was shown in an inducible expression system to affect protein stability 34 but did not change fluorescence intensity under constitutive expression when coupled with the S65T mutation (Fig. 2c) . A similar experiment using lentivirally integrated MS2-AID∆ and a single integrated sgRNA recovered the same S65T transition but not Q80H (Supplementary Fig. 4b ).
identification of bortezomib-resistant PsmB5 variants
Another application of CRISPR-X is the investigation of drug resistance mechanisms. Mutations are a common escape pathway for cancer cells to evolve resistance 37 ; understanding which mutations can arise would facilitate design of new drugs or drug combinations. To test this, we mutagenized PSMB5, a core subunit of the 20S proteasome, which is the target of the proteasome inhibitor bortezomib 38 . We generated a library of 143 guides tiling all coding exons of PSMB5 and a control library of 705 safe-targeting guides (Supplementary Data Set 2). These were lentivirally integrated into K562 cells expressing dCas9 and MS2-AID∆, given 14 d to develop mutations, and pulsed with bortezomib three times ( Fig. 3a) . After selection, PSMB5 exonic loci of both libraries were sequenced, and variant frequencies were quantitated at each base ( Fig. 3b and Supplementary Fig. 5a -c). The screen was performed in duplicate, and mutants enriched >20-fold in both replicates were selected for further analysis ( Fig. 3b and Supplementary Fig. 5c ). We identified 11 such mutations ( Fig. 3c) , including two (A108T and A108V) altering a residue known to be involved in binding bortezomib 39 . Novel mutations were identified near a threonine (residue 80) that also binds bortezomib (A74V, R78M, R78N, A79T, A79G, and G82D) which likely disrupt T80 and destroy the bortezomib binding pocket. Beyond mutations expected to affect the binding pocket, we identified two mutations in Exon 1 (L11L and G45G), an intronic mutation before Exon 2, and a mutation in Exon 4 (G242D) that is located on the side of the protein distal to the bortezomib binding pocket.
No resistant mutations were identified in alternate Exon 3, which is not expressed in K562 cells (data not shown). In the safe-targeted control library, we identified one mutation (A79T) that was also found with the PSMB5-targeted library and was likely present at undetectable levels in the parent K562 population ( Fig. 3b and Supplementary Fig. 5a -c).
We chose to functionally validate eight of these mutations by separately introducing each into the native PSMB5 locus using active Cas9 cutting followed by DNA donor oligonucleotide HDR 29, 30 . To control for the effect of Cas9 cutting and HDR, we knocked in a synonymous mutation not identified in our screen in each exon. Edited cells were selected with bortezomib for 14 d, and viability was quantified (Fig. 3d) . Five of the mutations (R78N, A79G, A79T, A108V, and G242D) were strongly protective against bortezomib-induced cell death, while the other three (L11L, Intronic, and G82D) showed more modest protection when compared to controls. For the most resistant mutations, the PSMB5 locus was sequenced following bort- the mutations induced by AID∆, with no noticeable increase in mCherry off-target mutation (Fig. 4a,b and Supplementary  Fig. 7a ). sgSafe.2 samples did not show mutation at either locus. We observed an increase in the size of the hotspot to −50 to +50 bp relative to the PAM (Fig. 4b) . Within this window, the most highly mutated bases were still located within the +12 to +32 region, suggesting the targeting pattern of AID*∆ had not changed compared with that of AID∆, but that increased mutation activity allowed for detection over a larger window. Within this region, we observed a substantially increased mutation rate (2.25-fold for sgGFP.3 and 6.52-fold for sgGFP.10) reaching over 20% of reads for sgGFP.10 ( Fig. 4b) as well as a modest increase in sequences with multiple mutations per read (1.32 mutations per read for AID*∆ versus 1.07 for AID∆; Supplementary Fig. 7b) .
To further explore the capacity of AID*∆-induced mutagenesis, we targeted three classes of endogenous loci: protein-coding genes, promoter regions, and safe-targeting regions. We targeted five sgRNAs to three highly expressed protein-coding genes (FTL, HBG2, and GSTP1), sequenced the respective loci, and quantitated mutation enrichment ( Fig. 4c and Supplementary Fig. 8a) . Additionally, we quantified mutation frequency at each base position relative to the PAM site ( Supplementary Fig. 8b and Fig. 4d) . We observed mutated bases in each of the three genes, with similar targeting in the −50 to +50 hotspot relative to the sgRNA PAM. To determine whether we could mutagenize genes with more moderate expression levels, as well as associated promoter regions, we targeted PTPRC, CD274, and CD14. For each locus, we observed mutated bases for sgRNAs targeting both upstream and downstream of the transcription start site (TSS; Fig. 4c and Supplementary Fig. 8a,b) . For CD274, we observed mutations targeted up to 3.2 kb upstream of the TSS, suggesting that some types of nontranscribed regions can be investigated using CRISPR-X. Lastly, we tested sgRNAs targeting four safe-targeting regions (nonfunctional genomic regions), but we did not observe mutations in these samples (data not shown), although we cannot rule out that this observation was due to ineffective sgRNAs or other factors.
We compared the mutation types observed for both AID∆ and AID*∆ within their respective hotspots (Fig. 4d) . The mutation rates were normalized by alternative allele frequencies observed in the parental samples within targeted hotspot regions. In addition, we calculated the s.d. of the alternative allele frequency in the parent samples when compared with reference sequence (5.68 × 10 −4 for AID∆ and 3.74 × 10 −4 for AID*∆), and we used this as a noise threshold for the transition-transversion frequencies. For both AID variants, we observed a preference for G>A and C>T transitions, with the most highly mutated bases being G or C (Fig. 4d) , consistent with the preference of AID deaminase activity. Importantly, we found a significant increase in mutation frequencies for all possible base changes except A>T for the AID*∆ samples. For both variants, low levels of insertions (maximum frequency of 1.98 × 10 −3 for AID*∆ and 7.44 × 10 −4 for AID∆) and deletions (maximum frequency of 5.15 × 10 −4 for AID*∆ and 3.01 × 10 −4 for AID∆) were observed. Thus, the increased activity of AID*∆ can expand the sequence space that can be mutagenized by a single sgRNA, including both coding and promoter regions of genes.
To quantitate the rate of mutation for AID*∆ over a range of sgRNAs, we tabulated mutation frequencies for each sgRNA over their respective 100-bp hotspots. Consistent with previous observations for Cas9, certain sgRNAs did not show activity, and we thus removed these (4/34 sgRNAs). To include an sgRNA in the analysis, we required that each replicate contained a base position in the hotspot that was enriched at least ten-fold over the parent population. 
Identified mutations Bortezomib-binding residues percent of reads containing a mutation and found that the median frequency was 0.0163, with ~25% of sgRNAs giving a frequency of >0.05 and up to 0.22 ( Supplementary Fig. 8c) .
To estimate the range of mutations that can be sampled using CRISPR-X in a population of cells, we quantified the diversity generated by AID*∆. Using data from the sgRNAs targeting GFP and the endogenous loci (Fig. 4b,c and Supplementary Fig. 8a) , we scanned across the region next to the PAM with a 21-bp window, which was the size of the AID∆ hotspot. In each window, we calculated the percentage of all 63 possible single-base variants (21 bases and 3 possible changes at each position) measured above the noise threshold in the population (Supplementary Fig. 8d) . While the efficiency of mutation varied with different sgRNAs, a window spanning from +20 to +40 from the PAM displayed the highest median percentage of possible variants (20.6%), and we observed up to 77.8% of all possible transitions in some cases. The +20 to +40 window is similar to the observed targeting hotspot for AID∆ (Fig. 4b) , suggesting that this region is the most highly mutagenized for both AID∆ and AID*∆.
Independent mutagenesis at multiple locations is typically not possible with traditional directed evolution experiments. However, the CRISPR-Cas9 system can target multiple loci using different sgRNAs 29, 30 . We found that coexpression of sgRNAs targeting GFP and mCherry resulted in a significant population of doublemutant cells (Supplementary Note 2 and Supplementary Fig. 9 ). Thus, CRISPR-X can be used to simultaneously mutagenize two sites within the same cell, suggesting targeted coevolution of two genomic loci should be possible.
discussion
Here we demonstrate that hyperactive AID targeted with dCas9 can be used to generate localized diversity within the mammalian genome at a rate comparable to that of somatic hypermutation, and that these mutagenized populations can be selected to evolve new protein function. This system, CRISPR-X, can simultaneously mutagenize multiple genomic loci, and it preserves reading frame by avoiding insertions and deletions observed with active Cas9. While the activity of AID in antibody maturation has been shown to require transcription 11 , we observed mutations above background for sgRNAs targeting both upstream and downstream of the TSS. Although regions upstream of the TSS may be transcribed at lower levels, these findings suggest that CRISPR-X is not bound to regions downstream of annotated TSSs and could allow for the engineering and investigation of promoters, enhancers, and other regulatory elements.
Using CRISPR-X, we highlight several examples of directed evolution. First, we show that GFP can be readily evolved to EGFP with an appropriately designed sgRNA and targeted AID.
In addition, we demonstrate that mutagenesis of the target of the chemotherapeutic bortezomib (PSMB5) reveals both known and novel mechanisms of resistance. In this experiment, we found the A108V and A108T mutation identified in bortezomib-resistant cell lines 39, 41 and colorectal cancer samples 42 , and other mutations consistent with the disruption of the binding pocket of bortezomib. Interestingly, we uncovered a mutation located in Exon 4 (G242D), which had not been previously connected to bortezomib resistance and is located on the side of the protein opposite the bortezomib pocket (Fig. 3d) . This could suggest additional mechanisms of resistance and may inform study of PSMB5 function and future drug design. Additionally, we identified synonymous and intronic mutations which require further study.
CRISPR-X represents an efficient strategy to create a diverse library of point mutations in situ, expanding the repertoire of methods for genome engineering using Cas9. Mutagenesis using active Cas9 has been effective for inducing insertions and deletions, which can disrupt functional elements 28, 43, 44 and inactivate protein function [29] [30] [31] 45 . During the preparation of our manuscript, two elegant studies demonstrated that dCas9 can be used to recruit deaminases for the remarkably precise conversion of C > T within a 5-bp window, as a way to correct single base changes observed in disease 24, 27 . Here, we show that a hyperactive AID variant can create dense, highly variable point mutations within a region of 100 bp surrounding an sgRNA target site at a rate of up to ~1/500-1/1,000 bp −1 (Fig. 4b) , compared with the mutation rate during cellular DNA replication of ~1/10 9 bp −1 (ref. 46) . As in antibody somatic hypermutation, we observed a large variety of transitions and transversions from C and G bases to all possible bases (rather than just C>T and G>A described in previous studies) and a low level of all base changes (Fig. 4d) . Using this diverse population of mutants, we demonstrate that we are able to select for the evolution of new function.
CRISPR-X presents a number of significant advantages for engineering targeted genomic diversity. Previous work has demonstrated a powerful strategy by which active Cas9 can be used to introduce mutant oligonucleotide donor libraries by homologous recombination; the resulting cell populations can be used to study RNA and protein function in mammalian cells 33 or select for improved fermentation in yeast 32 . However, this strategy requires the separate synthesis of a mutant donor library for each engineered site. In contrast, CRISPR-X repurposes the somatic hypermutation machinery, making it possible to generate a library of point mutations in situ using a single sgRNA and even greater diversity through multiplexing or multiple rounds of sgRNA library electroporation. In addition, targeting of AID should allow continuous mutagenesis and evolution of protein function.
While elegant work has been done to understand targeting of somatic hypermutation to the Ig locus 10, 47 , the known control elements would be difficult to install systematically throughout the genome. CRISPR-X overcomes this limitation by using dCas9 to target somatic hypermutation, and thus should facilitate both engineering of new biomolecules as well as an understanding of the SHM process itself. We envision that this system should make it possible to study the coevolution of two interacting proteins and could provide a streamlined strategy for selection of enhanced antibody and enzyme function via mutagenesis in native context. 
online methods
Step-by-step protocol. A protocol for CRISPR-X is available in Supplementary Note 2.
Design and construction of CRISPR-X and fluorescent protein plasmids. A list of the plasmids and primers used are listed in Supplementary Data Set 1. Lenti dCAS-VP64_Blast, lenti MS2-P65-HSF1_Hygro, and lenti sgRNA(MS2)_zeo backbone were a gift from Feng Zhang (Addgene plasmids 61425, 61426, and 61427). The VP64 effector was removed from the dCas9 construct by digestion with BamHI and EcoRI followed by Gibson assembly to reinsert PCR-amplified blasticidin resistance marker (pGH125). For the MS2 fusions, the P65-HSF1 was removed using restriction digest with BamHI and BsrGI. AID (pGH156) and AID∆ (pGH153) were PCR amplified from a FLAG-AID-expressing plasmid, courtesy of the Cimprich Lab, and Gibson assembled into the digested vector. Catalytically inactive (pGH183) and hyperactive mutants (pGH335) were generated using PCR primers containing the desired mutations. Subunits of AID were amplified using those primers and then joined using overlapping PCR. The mutant AID PCR product was Gibson assembled into the digested MS2 expression vector. GFP-, mCherry-, and wtGFP-expressing plasmids driven by an Ef1α promoter were generated using pMCB246, which was digested with NheI and XbaI, removing a puromycin resistance T2A-mCherry cassette. GFP (pGH045) and mCherry (pGH044) were PCR amplified and inserted into the digested vector using Gibson assembly. Variants of GFP (wtGFP (pGH220)) and identified mutants (pGH311-S65T, pGH312-Q80H, pGH314-S65T-Q80H) were constructed using the previously described overlapping PCR method followed by Gibson assembly. Plasmid maps of these constructs are available upon request. For dual-guide experiments, a second sgRNA-expressing plasmid was constructed by removing the zeocin resistance (digestion of lenti sgRNA(MS2)_zeo with BsrGI and EcoRI) and replaced with puromycin resistance with a removed BsmBI cut site by Gibson assembly (pGH224). sgRNA vectors were generated by digesting either lenti sgRNA(MS2)_zeo or pGH224 with BsmBI. Oligonucleotides with overhangs compatible with subsequent ligation were designed and annealed followed by ligation into the digested vector. The sequence for the sgRNAs are listed in the Supplementary Data Set 1. All plasmid sequences were verified using Sanger sequencing. All oligonucleotides were ordered from Integrated DNA Technologies (IDT).
Cell culture and generating parent cell lines. Lentiviral production as well as infection and culturing of K562 cells (ATCC) were performed as described 48 . Parental K562 cell lines were generated by infecting dCas9-Blast (pGH125) followed by blasticidin selection (10 µg/mL, Gibco) for 7 d. Cells were subsequently infected with both GFP (pGH045) and mCherry (pGH044) expression vectors or with a wtGFP (pGH220) expression vector and sorted via fluorescence-activated cell sorting (FACS) for fluorescence. These cell lines were used as the parental samples in the sequencing assays. For integrated CRISPR-X experiments, these cells were infected with MS2-AID (pGH153, pGH156, pGH183, and pGH335)-expressing vectors followed by selection with hygromycin B (200 µg/mL, Life Technologies) for 7 d. All cell lines were maintained in a humidified incubator (37 °C, 5% CO 2 ) and checked regularly for mycoplasma contamination.
Fluorescence microscopy of MS2-AID localization. K562 cells were lentivirally infected by constructs expressing an MS2-AID∆ (pGH153) and MS2-AID (pGH156) and selected with hygromycin B for 7 d. 1 million cells were harvested and fixed in 4% paraformaldehyde for 15 min at room temperature. Cells were washed three times with PBS and then permeabilized with 0.1% Triton-X in PBS for 10 min at 4 °C. Cells were incubated in blocking solution (3% BSA in PBS) for 1 h at room temperature. They were centrifuged at 500 g for 5 min and resuspended in 1:500 dilution of rabbit anti-MS2 antibody (Millipore, cat no. ABE76) in blocking solution for 2 h at room temperature. The cells were washed three times with PBS and resuspended in 1:1,000 dilution of Alexa Fluor 488 conjugated goat anti-rabbit antibody (Life Technologies) in blocking solution and incubated for 2 h at room temperature. Cells were washed in PBS three times and resuspended in Vectashield (Vector Laboratories) containing DAPI. The samples were deposited on a glass coverslip and imaged using an inverted Nikon Eclipse Ti confocal microscope with 488 nm (AlexaFluor488) and 405 nm (DAPI) lasers, an oil immersion objective (Plan Apo λ, numerical aperture (NA) = 1.5, 100×, Nikon), and an Andor Ixon3 EMCCD camera. Images were processed using ImageJ (National Institutes of Health).
Comparison of MS2-AID variant expression. K562 cells were infected with constructs expressing MS2-AID (pGH156), MS2-AID∆ (pGH153), and MS2-AID*∆ (pGH335) and selected with hygromycin B for 7 d. 1.2 million cells were harvested and rinsed once with ice-cold PBS before being lysed in lysis buffer (1% Triton X-100, 150 mM NaCl, 50 mM Tris pH 7.5, and 1 mM EDTA) for 20 min on ice. Debris was removed by centrifugation for 10 min at 21,000 g at 4 °C. The supernatant was collected, and protein was quantified for each sample using DC Protein Assay (Bio-Rad). For each sample, 100 µg of protein was denatured under reducing conditions (NuPAGE LDS Sample Buffer (4×), Life Technologies, cat no. NP0007, and 100 mM DTT), loaded on a 4-12% Novex BisTris SDS-PAGE gel (Life Technologies), and analyzed by immunoblot using a rabbit anti-MS2 antibody (1:1,000 dilution, Millipore, cat no. ABE76) and mouse anti-GAPDH antibody (1:4,000 dilution, Life Technologies, cat no. AM4300). Donkey anti-mouse IRDye 680 LT and goat anti-rabbit IRDye 800CW (1:20,000 dilution, LI-COR Biosciences, cat nos. 925-68022 and 925-32211, respectively) were used as secondary antibodies. Immunoblots were imaged using an Odyssey infrared imaging system (LI-COR Biosciences).
Transient electroporation of K562 cells and testing MS2-AID variants.
Nucleofection of K562 cells was performed as described 49 . 1 million K562 cells were harvested for each electroporation. Cells were centrifuged at 300 g for 5 min and resuspended in 100 µL of nucleofection solution and mixed with plasmid DNA (5 µg MS2-AID-expressing plasmid and 5 µg sgRNA expression vector) and loaded into a 2 mM cuvette (VWR). Electroporations were performed using the T-016 program on the Lonza Nucleofector 2b. After electroporation, cells were rescued in warm supplemented RPMI media. Cells were grown for 10 d, and the GFP and mCherry fluorescence was measured using the BD Accuri C6 flow cytometer. The scatter plots shown were generated in FlowJo. The cells were sorted for low GFP fluorescence, and the cells were grown before preparation of sequencing.
Generating mutations from individual and dual-sgRNA experiments. For integrated CRISPR-X experiments, 3 d after infection, selection was applied and continued for 11 d using blasticidin for dCas9, hygromycin B for MS2-AID variants, and zeocin (200 µg/mL, Life Technologies) for sgRNA. For dualsgRNA experiments, the sgGFP.10 plasmid was further selected using puromycin (1 µg/mL, Sigma-Aldrich). For GFP-and mCherry-targeting sgRNAs, the GFP and mCherry fluorescence was measured after selection using a BD Accuri C6 flow cytometer. Scatter plots shown were generated in FlowJo. Experiments targeting GFP or mCherry were performed with three biological replicates, while endogenous loci were performed with two biological replicates.
Preparation of sequencing samples. To sequence the targeted loci, genomic DNA was extracted from 0.5-1.5 million cells using the QiaAmp DNA mini kit (Qiagen). The targeted loci were PCR amplified from 0.5-1 µg of genomic DNA using primers shown in Supplementary Data Set 1. The product was purified on a 0.8-1% TAE agarose gel. The concentration was measured by Qubit (Life Technologies) and then prepared for sequencing following the Nextera XT kit protocol (Illumina). For PSMB5 experiments, DNA was extracted from 20 million cells, and PCR amplification was performed on 5 µg of genomic DNA. After individual gel purification of PCR product from each exon, PCR products were mixed in equimolar amounts before beginning the Nextera XT preparation.
Sequences were measured on a NextSeq 500 (Illumina) with paired-end reads of length 76 or 151 bp. Every sequencing run included a parental sample for each locus that was being sequenced.
Analysis of sequencing data. Sample sequencing and alignment.
Over all sequenced samples, 4.5 million reads were produced on average. Sequencing adapters (5′ adaptor, CTGTCTCTTATACAC ATCTCCGAGCCCACGAGAC; 3′ adaptor, CTGTCTCTTATACAC ATCTGACGCTGCCGACGA) were trimmed using cutadapt (version 1.8.1, ref. 50), also discarding reads under 30 bp and nucleotides flanking the adapters with Illumina quality score lower than 30 (leaving only flanking sequences for which the basecall accuracy is over 99.9%). Alignment on respective reference loci was performed using bwa aln (v0.7.7) and bwa samse 51 . A maximum number of three or five mismatches was allowed for samples with read length of 76 bp and 151 bp, respectively. Aligned files were then sorted using samtools (v0. 1.19, ref. 52) .
Only reads aligned to their respective references with mapping quality over 30 were kept for further analysis. On average, 90% of sequenced reads (s.d. 16%) were successfully mapped to the provided reference genome. From these aligned reads, 96% (s.d. 5.7%) remained after filtering on mapping quality.
Tabulation of mutations per base. We computed allelic counts at each position with a custom script after filtering for nucleotides with Illumina base-quality score over 30 using samtools mpileup (version 1.2). The parental sample was used to estimate the mutations introduced through sample preparation and sequencing. Using the parental as a reference, we calculated the mutation enrichment at each base by comparing the percentage of reads with alternative alleles with the same proportion calculated in the parental sample. For frequency of mutation calculated at each base, we subtracted the frequency of alternative alleles in the parental sample from the frequency calculated for the mutated sample. The first and last 50 bases of each locus were excluded from these enrichments, given that the ends had lower read coverage that was a byproduct of the Nextera XT preparation. We calculated the transitions, transversions, and indels observed in the hotspots by looking at the distribution of frequencies of every possible alternative nucleotide at each position. We then subtracted the respective frequencies of the parental cell lines in the hotspots to take into account the background noise. Negative values were set to 0. To estimate the remaining noise resulting from sequencing and variability between samples, we calculated the s.d. of the frequency of alternative alleles in all parental samples from the studied batch (Fig. 4d) . Reported medians, maximums, and distributions resulted from this calculation.
Calculation of mutation frequency in hotspot regions. The number of mutations per read was limited during the alignment step (see above). We performed mutation counts from the filtered aligned data to compute the enrichment of reads carrying mutations within the hotspot. After selecting all reads overlapping the hotspot using samtools view (version 1.2, ref. 52), each read was screened for mutations within the respective hotspot regions. These results were then summarized for each sample by calculating the ratio between the number of reads with mutations spanning the hotspot and the total number of reads spanning the hotspot. The frequency of mutations enrichment was calculated by subtracting the results from the parental cell line as background.
Calculation of the observed percentage of possible transitions. To estimate mutant diversity in a population of cells, we analyzed the hyperactive AID*∆ mutant samples (Fig. 4b,c) with a custom R script. For each sgRNA-targeted sample, we selected the mutation hotspot (±50 bp with respect to the PAM) and computed the frequency of each observed alternate allele. At each position we subtracted the respective allelic frequency observed in the corresponding parent sample. Using a sliding window of 21 bp over the hotspot and the 20 bp flanking each end, we calculated the percentage of all 63 possible transitions in the window that were observed above noise. Noise was defined as the s.d. of the alternative allele frequency among all parent samples. Results were then output by window as a boxplot representing the combination of all considered sgRNA-targeted samples.
Evolution of wtGFP to EGFP using CRISPR-X. For transient electroporation wtGFP experiments, K562 cells expressing dCas9 and wtGFP were electroporated as described earlier with 5 µg of MS2-AID∆ and either 1.25 µg for each of wtGFP.1-4 or Safe.2,4-6 sgRNA-expressing vectors. Cells were grown for 10 d after electroporation before sorting. For integrated experiments, K562 cells expressing dCas9, MS2-AID∆, and wtGFP were infected with either wtGFP.1 or Safe.2 sgRNA-expressing vectors. After 3 d, cells were selected with blasticidin, hygromycin B, and zeocin for 11 d. Cells were sorted via FACS to obtain spectrum-shifted GFP variants. For the electroporation experiments, cells were grown for 7 d between sorting rounds. Samples were prepared for sequencing as described previously.
Flow cytometry of wtGFP variants. HEK293T (ATCC) cells were cultured in DMEM with 10% FBS, penicillin-streptomycin, and L-glutamine. For each transfection, 1 million HEK293T cells were plated in 2 mL of supplemented DMEM media. 1.5 µg of wtGFPexpressing plasmid (pGH045, pGH220, pGH311, pGH312, and pGH314) was mixed with 200 µL serum-free DMEM and 10 µL of polyethylenimine (PEI, 1 mg/mL, pH 7.0, PolySciences Inc.) and incubated at room temperature for 30 min. The mixture was added to the cells and grown for 72 h with an additional 3 mL of DMEM supplemented media added after 24 h. The samples were trypsinized and analyzed using a FACScan flow cytometer (BD Biosciences). Additional analysis of the data was performed using FlowJo.
Design and construction of PSMB5 tiling libraries. The PSMB5 tiling library was generated using the CHOPCHOP online tool 53 for the three PSMB5 isoforms (NM_0011449632, NM_00130725, and NM_002797). sgRNAs for each isoform were combined. sgRNAs having any genomic off-target matches, more than one off-target when allowing one mismatch in the sgRNA sequence, or five or more off targets when allowing one or two mismatches within the sgRNA sequence were removed. The sgRNAs were further filtered by removing any containing a BsmBI cut site, which interferes with the library cloning strategy. The final library contained 143 sgRNAs. Safe-targeting sgRNAs were designed to target genomic loci that have not been annotated to include gene exons or untranslated regions (UTRs), have signal in biochemical assays (DNaseI, CHIP-Seq, etc.), or have signal in sequence-based analyses (conserved elements, transcription factor motif searches, etc.). The design and selection of these sgRNAs will be discussed in more detail in future work (personal communication). 705 safe-targeting sgRNAs were selected to serve as a control library. The sgRNA sequences for both libraries are included in Supplementary Data Set 2.
Oligonucleotide libraries were synthesized by Agilent and cloned into the sgRNA expression vector as previously described [54] [55] [56] . Vector and sgRNA inserts were digested with BsmBI. Large-scale lentivirus production and infection of K562 cells were performed as described 54, 56 . 3 d after infection, selection began with blasticidin, hygromycin B, and zeocin for 11 d. Cells were expanded to 20 million cells for each treatment (safe-targeted and PSMB5 libraries in duplicate) and were pulsed with 20 nM bortezomib (Fisher Scientific) for 3 d followed by recovery until log growth was restored (5-10 d) before the next pulse. The cells were pulsed a total of three times. After the final pulse, cells were harvested and prepared for sequencing as described earlier.
Installation and validation of bortezomib-resistant PSMB5 mutations. sgRNAs were designed to target near the location of the installed SNP, and 101 nt donor oligonucleotides were designed to be centered around the installed mutation. Oligonucleotides with proper overhangs were ordered from IDT and annealed before ligation into BbsI-digested pGH020, a hu6-driven sgRNA expression vector. All plasmids were verified by Sanger sequencing. The sgRNA and ssDNA donor oligonucleotide sequences are listed in Supplementary Data Set 1.
K562 cells expressing Cas9 were electroporated with 5 µg of sgRNA-expressing vector and 100 picomoles of donor oligo. Cells were grown for 6 d before 300,000 cells were placed under selection with 20 nM bortezomib for 14 d. The viability of the cells was measured by flow cytometry using a live-cell gate (FSC/SSC). After selection, 750,000 cells were harvested, and genomic DNA was extracted using the QiaAmp DNA Mini Kit (Qiagen). The PSMB5 exonic locus containing the mutation was PCR amplified, gel purified, and ligated into the pCR-Blunt vector using the ZeroBlunt cloning kit (Life Technologies). 8-15 colonies were Sanger sequenced for each sample.
